Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.
Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center
Advertisement
Articles by Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center
Advertisement
Latest Updated Articles
Metastatic Breast Cancer: Chemotherapy SelectionJanuary 26th 2021
Assessing Response to Chemotherapy in Metastatic Breast CancerJanuary 19th 2021
MBC Therapy: Tesetaxel/CapecitabineFebruary 16th 2021
Treatment Advances in Metastatic Breast CancerJanuary 19th 2021
Using Oral Therapies to Advance Care in MBCFebruary 16th 2021
At-Home Administration of Therapies to Treat MBCFebruary 9th 2021
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
Precision Advances Have Transformed Lung Cancer Care, But Key Barriers Persist
4
FDA Awards Orphan Drug Designation to Enzomenib for ALL
5